依奇珠单抗改善生物制剂初治活动性银屑病关节炎患者患者报告结局至52周(SPIRIT-P1)
SPIRIT-P1研究纳入生物制剂初治活动性银屑病关节炎患者,随机接受依奇珠单抗80mg每4周(107例)或每2周(103例,起始160mg)、阿达木单抗40mg每2周(101例)或安慰剂(106例)治疗24周双盲期,第24周后阿达木单抗和安慰剂组重随机至依奇珠单抗每2周或每4周治疗至52周。结果显示依奇珠单抗组在DLQI、瘙痒NRS、SF-36v2躯体成分评分、EQ-5D VAS及部分WPAI-SHP领域显著改善。
要点
- 依奇珠单抗每4周和每2周组及阿达木单抗组第24周DLQI均显著改善。
- 第24周DLQI评分为0或1的患者比例:安慰剂22%、依奇珠单抗每4周53%、每2周63%、阿达木单抗54%。
- 依奇珠单抗组第12周和第24周瘙痒NRS、SF-36v2躯体成分评分及部分领域、EQ-5D VAS显著改善。
核心结论
- 在生物制剂初治活动性银屑病关节炎患者中,依奇珠单抗显著改善皮肤症状、健康相关生活质量和工作生产力。
研究设计与样本
- SPIRIT-P1研究为随机对照试验,生物制剂初治活动性银屑病关节炎患者随机接受依奇珠单抗80mg每4周(107例)或每2周(103例,起始160mg)、阿达木单抗40mg每2周(101例)或安慰剂(106例)治疗24周双盲期。
主要发现
- 第24周依奇珠单抗每4周、每2周和阿达木单抗组DLQI均显著改善;DLQI评分为0或1的患者比例分别为每4周53%、每2周63%、阿达木单抗54%、安慰剂22%。
- 第12周和第24周依奇珠单抗每4周、每2周和阿达木单抗组瘙痒NRS、SF-36v2躯体成分评分及部分领域评分、EQ-5D VAS均显著改善。
- 第24周依奇珠单抗每4周、每2周和阿达木单抗组在WPAI-SHP四个领域中的三个领域显著改善。
- 第24周后阿达木单抗和安慰剂组重随机至依奇珠单抗每2周或每4周,结果也呈现至第52周。
关键数值与推荐
- 第24周DLQI评分为0或1的患者比例:安慰剂22%、依奇珠单抗每4周53%、依奇珠单抗每2周63%、阿达木单抗54%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report patient-reported outcomes of patients with PsA treated with ixekizumab up to 52 weeks. METHODS: In SPIRIT-P1, biologic-naïve patients with active PsA were randomized to ixekizumab 80 mg every 4 weeks (IXEQ4W; N = 107) or every 2 weeks (IXEQ2W; N = 103) following a 160 mg starting dose, adalimumab 40 mg every 2 weeks (ADA; N = 101) or placebo (PBO; N = 106) during the initial 24-week double-blind treatment period. At week 24 (week 16 for inadequate responders), ADA (8-week washout before starting ixekizumab) and PBO patients were re-randomized to IXEQ2W or IXEQ4W. Patients receiving ixekizumab at week 24 received the same dose during the extension period (EP) to week 52. Patients completed measures including the Dermatology Life Quality Index (DLQI), Itch Numeric Rating Scale, 36-Item Short Form Health Survey version 2, European Quality of Life 5 Dimensions Visual Analogue Scale and Work Productivity and Activity Impairment Questionnaire-Specific Health Problem. RESULTS: The IXEQ4W, IXEQ2W and ADA groups reported significant improvements in DLQI at week 24; 22% (PBO), 53% (IXEQ4W), 63% (IXEQ2W) and 54% (ADA) of patients reported DLQI scores of 0/1. The IXEQ4W, IXEQ2W and ADA groups reported significant improvements in Itch Numeric Rating Scale, 36-Item Short Form Health Survey version 2 physical component summary and some domain scores, and European Quality of Life 5 Dimensions Visual Analogue Scale at weeks 12 and 24; and in three of four Work Productivity and Activity Impairment Questionnaire-Specific Health Problem domains at week 24. Results are also presented through week 52 for the EP. CONCLUSION: In biologic-naïve patients with active PsA, ixekizumab significantly improved skin symptoms, health-related quality of life and work productivity. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01695239; EU Clinical Trials Register, https://www.clinicaltrialsregister.eu, EudraCT2011-002326-49.
引用
- Gottlieb AB, Strand V, Kishimoto M, et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018. PMID: 29945203. doi:10.1093/rheumatology/key161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。